Carcinoid Tumors
15
0
0
7
Key Insights
Highlights
Success Rate
58% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
33.3%
5 terminated out of 15 trials
58.3%
-28.2% vs benchmark
13%
2 trials in Phase 3/4
129%
9 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors